Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data.

JTO clinical and research reports·2026

Same author

Machine learning integrated extracellular vesicle proteome analysis for early markers of bronchopulmonary dysplasia.

Function (Oxford, England)·2026

Same author

Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having <i>EGFR</i> Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer-American Society of Clinical Oncology CancerLinQ Study.

JTO clinical and research reports·2024

Same author

Characterization of effective, simple, and low-cost precipitation methods for depleting abundant plasma proteins to enhance the depth and breadth of plasma proteomics.

Proteomics·2024

Same author

International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2023

Same author

Design of experiments approach for systematic optimization of a single-shot diaPASEF plasma proteomics workflow applicable for high-throughput.

Proteomics. Clinical applications·2023

Search research articles

Related Experiment Video

Updated: May 26, 2026

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Volociximab in cancer.

Salah Almokadem¹, Chandra P Belani

¹Penn State Hershey Medical Center, Department of Medicine, Hershey, PA, USA.

Expert Opinion on Biological Therapy

|December 24, 2011

Summary

This summary is machine-generated.

Volociximab, an antibody targeting α5β1 integrin, shows promise in treating solid tumors by inhibiting angiogenesis. Clinical trials indicate it is well-tolerated and effective, warranting further randomized studies.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: May 26, 2026

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

Volociximab is a novel chimeric monoclonal antibody targeting the α5β1 integrin receptor.
Preclinical data demonstrate its potential to inhibit tumor angiogenesis by blocking α5β1 integrin-fibronectin interactions.

Purpose of the Study:

To review the biological effects of volociximab.
To summarize findings from completed clinical trials evaluating volociximab in solid tumors.

Main Methods:

Review of scientific literature on integrin α5β1, fibronectin, and volociximab.
Analysis of preclinical and clinical study data for volociximab's efficacy and safety.

Main Results:

Volociximab has a well-established safety profile and pharmacokinetic/pharmacodynamic characteristics.
Early clinical trials suggest promising anti-cancer activity for volociximab as a single agent or in combination therapy.

Conclusions:

Volociximab is well-tolerated in monotherapy and combination regimens.
Further randomized clinical trials are necessary to confirm the efficacy of volociximab in various cancer types.